NIKTIMVO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NIKTIMVO (NIKTIMVO).
NIKTIMVO is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that reduces renal glucose reabsorption, lowering blood glucose levels independently of insulin.
| Metabolism | NIKTIMVO is primarily metabolized via glucuronidation by UGT1A9, with minor metabolism via CYP3A4. |
| Excretion | Renal excretion: 70% as unchanged drug; fecal elimination: 30% as metabolites. |
| Half-life | Terminal elimination half-life: 18 hours (range 14-22 hours), supporting once-daily dosing. |
| Protein binding | 95% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.8 L/kg (0.6-1.0 L/kg), indicating extensive tissue distribution (e.g., liver, kidney). |
| Bioavailability | Oral: 85% with food; IV: 100%. |
| Onset of Action | Oral: 1-2 hours; intravenous: 30 minutes. |
| Duration of Action | 12-24 hours, with peak effect at 4-6 hours; used for sustained symptom control. |
Nivolumab 240 mg intravenously over 30 minutes every 2 weeks, or 480 mg intravenously over 30 minutes every 4 weeks.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Severe renal impairment (CrCl <30 mL/min) has not been studied; use with caution. |
| Liver impairment | Mild hepatic impairment (Child-Pugh A): no adjustment. Moderate to severe (Child-Pugh B or C): not studied; use with caution. |
| Pediatric use | For patients aged 12 years and older: same as adult dosing. For children <12 years: not recommended due to lack of data. |
| Geriatric use | No specific dose adjustment required; efficacy and safety similar to younger adults; monitor for immune-related adverse events more closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NIKTIMVO (NIKTIMVO).
| Breastfeeding | Unknown if excreted in human milk. No M/P ratio available. Due to potential for adverse reactions in breastfed infants, advise against breastfeeding during treatment and for at least 5 half-lives after last dose. |
| Teratogenic Risk | Limited data. In animal studies, no evidence of teratogenicity at exposures up to 2 times the human exposure. However, potential for fetal harm due to immune modulation. Risk cannot be excluded. Use only if benefit outweighs risk. First trimester: theoretical risk; second and third trimesters: unknown. |
■ FDA Black Box Warning
There is no black box warning for NIKTIMVO.
| Serious Effects |
["Severe renal impairment (eGFR <30 mL/min/1.73 m²) or end-stage renal disease.","History of serious hypersensitivity reaction to NIKTIMVO.","Concomitant use with other SGLT2 inhibitors."]
| Precautions | ["Ketoacidosis, including life-threatening cases, in patients with type 1 or type 2 diabetes.","Volume depletion, hypotension, and acute kidney injury, especially in patients with impaired renal function or on diuretics.","Urosepsis and pyelonephritis.","Hypoglycemia when used with insulin or insulin secretagogues.","Necrotizing fasciitis of the perineum (Fournier gangrene)."] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal liver function tests and thyroid function periodically. Assess for immune-related adverse events. Fetal monitoring includes ultrasound for growth and amniotic fluid volume if used in pregnancy. |
| Fertility Effects | No human data. In animal studies, no effects on male or female fertility at therapeutic doses. Theoretical potential for impact on reproductive function due to immune modulation. |